NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Next generation sequencing consumables instruments and related services will reach $5.6 billion dollars by 2019, according to Kalorama Information. The healthcare market research publisher said that the use of NGS for research, clinical testing and even consumer purposes will drive sales of sequencers and related products. The finding was made in the firm's recent report, Next Generation Sequencing (NGS) Markets 2015.
The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized.
Kalroama notes the following trends in its market assessment:
- Multiple Applications: Research, Clinical and even Consumer
- Growing Installed Base in Developed Countries: US, Europe and Japan
- Emerging Nations. China, South Korea and Brazil Among Fast-Growth Markets
- Development of Commercialized Kit Products
- Involvement of Top Healthcare Names
- Investor Interest: Note Recent $100M Investment in Illumina's Helix
- Agreements Between Pharmaceutical Companies Will Drive Growth
Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. Kalorama uses analysis of previous revenue growth, the number of entrants in the industry, and interviews with market experts to develop its forecasts.
Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model.
Kalorama Information's Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends) comprehensively analyzes research and clinical markets for NGS as well as transformative iterations of the technology already edging into "third-generation sequencing" territory.
Find more information on the report by visiting: http://www.kaloramainformation.com/redirect.asp?progid=87595&productid=8743599.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
KaloramaInformation.com
240.747.7418
Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO
SOURCE Kalorama Information
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article